US judge overturns Eli Lilly USD 176.5 million loss in Teva patent case

Published On 2023-09-27 07:15 GMT | Update On 2023-09-28 04:24 GMT

Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly's migraine drug Emgality infringed three patents related to Teva's rival drug Ajovy.

U.S. District Judge Allison Burroughs said in a post-trial ruling that the Teva patents covering the use of antibodies to inhibit headache-causing peptides were invalid.

"The Court does not reach this decision nor overturn a jury verdict lightly," Burroughs said.

Representatives for the companies did not immediately respond to requests for comment on the decision.

Eli Lilly earned more than $650 million from Emgality sales worldwide last year, while Teva earned $377 million from Ajovy, according to company reports.

Teva sued Lilly over the patents in 2018. On the same day that Teva sued, the court dismissed two related Teva lawsuits seeking to block Emgality from coming on to the U.S. market.

A jury awarded Teva $176.5 million in damages in November and rejected Lilly's argument that the patents were invalid.

Burroughs reversed the jury's validity decision on Tuesday. She concluded that the patents were overly broad and did not enable scientists to recreate the antibodies without "undue experimentation."

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

US judge overturns Eli Lilly USD 176.5 million loss in Teva patent case

Similar News

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

Delhi to form special committee to crush fake medicine racket

Roche Pharma teams up with 10 Govt Hospitals to power up clinical trial capacities in India

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

Govt Allows Stickering, Orders New MRPs Post GST Reduction, AiMeD Welcomes Directive

Sun Pharma Secures Interim Court Relief In URSOCOL Trademark Dispute

Nellore Horror: 21-year-old B.Pharm student stabbed to death

Upcoming Una Bulk Drug Park receives environmental clearance